All In Biotech

Drug Trial Radar · NCT06670950

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

A Two-Part Study Investigating The Relative Bioavailability And The Potential Food Effect After A Single Oral Dose Administration Of A New Formulation of SYT-510, And The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Oral Dose Administration Of SYT-510 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Nov 4, 2024

Primary completion

May 17, 2025

Study completion May 23, 2025

Sponsor

Lead sponsor
Synendos Therapeutics AGIndustry
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510. Part 1 will then guide dosing in Part 2, a multiple dose study which aims to assess safety, tolerability and pharmacokinetic of multiple SYT-510 administrations.

Conditions

  • Healthy

Interventions

  • SYT-510Drug

    Oral formulation A fasted

  • SYT-510Drug

    Oral formulation B fasted

  • SYT-510Drug

    Oral formulation A fed

  • PlaceboDrug

    Oral formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum Observed Concentration (Cmax) of SYT-510Time frame: Up to 72 hours post-dose
  2. Part 1: Area under the concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of SYT-510Time frame: Up to 72 hours post-dose
  3. Part 1: AUC of SYT-510Time frame: Up to several days post last dose
  4. Part 2: Incidence and severity of treatment related adverse event, including abnormal laboratory events to evaluate the safety and tolerability profile of multiple ascending doses of SYT-510Time frame: Up to Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond Pharmacology Ltd

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.